{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:28:53Z","timestamp":1772166533443,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2020SK53419"],"award-info":[{"award-number":["2020SK53419"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82302449"],"award-info":[{"award-number":["No.82302449"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Launch Project for New Employees of the Second Xiangya Hospital of Central South University"},{"name":"Health Research Project of Hunan Provincial Health Commission","award":["W20243115"],"award-info":[{"award-number":["W20243115"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-025-01899-9","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T15:32:40Z","timestamp":1748878360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of DNA methylation on the recurrence risk of stage I non-small cell lung cancer with EGFR mutations"],"prefix":"10.1186","volume":"17","author":[{"given":"Yunyi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingchun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm V.","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"1","key":"1899_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","volume":"19","author":"WZ Zhong","year":"2018","unstructured":"Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1\u2013N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139\u201348.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1899_CR2","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","volume":"41","author":"RS Herbst","year":"2023","unstructured":"Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023;41(10):1830\u201340.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1899_CR3","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711\u201323.","journal-title":"N Engl J Med"},{"issue":"2","key":"1899_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohe C, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023;389(2):137\u201347.","journal-title":"N Engl J Med"},{"issue":"5","key":"1899_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022 NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497\u2013530.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"1899_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","volume":"33","author":"A Passaro","year":"2022","unstructured":"Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022;33(5):466\u201387.","journal-title":"Ann Oncol"},{"key":"1899_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.athoracsur.2023.01.024","volume":"117","author":"A Kamigaichi","year":"2023","unstructured":"Kamigaichi A, Mimae T, Tsubokawa N, Miyata Y, Adachi H, Shimada Y, et al. Risk factors for recurrence of stage I epidermal growth factor receptor mutated lung adenocarcinoma. Ann Thorac Surg. 2023;117:743.","journal-title":"Ann Thorac Surg"},{"issue":"11","key":"1899_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.31892","volume":"4","author":"SPL Saw","year":"2021","unstructured":"Saw SPL, Zhou S, Chen J, Lai G, Ang MK, Chua K, et al. Association of clinicopathologic and molecular tumor features with recurrence in resected early-stage epidermal growth factor receptor-positive non-small cell lung cancer. JAMA Netw Open. 2021;4(11): e2131892.","journal-title":"JAMA Netw Open"},{"key":"1899_CR9","doi-asserted-by":"crossref","unstructured":"Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K (2011) Poor prognostic factors in patients with stage IB non-small cell lung cancer according to the seventh edition TNM classification. Chest. 139(4):855\u201361","DOI":"10.1378\/chest.10-1535"},{"issue":"19","key":"1899_CR10","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1158\/1078-0432.CCR-22-0879","volume":"28","author":"HA Jung","year":"2022","unstructured":"Jung HA, Lim J, Choi YL, Lee SH, Joung JG, Jeon YJ, et al. Clinical, pathologic, and molecular prognostic factors in patients with early-stage EGFR-mutant NSCLC. Clin Cancer Res. 2022;28(19):4312\u201321.","journal-title":"Clin Cancer Res"},{"key":"1899_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.lungcan.2020.01.018","volume":"141","author":"M Ito","year":"2020","unstructured":"Ito M, Miyata Y, Tsutani Y, Ito H, Nakayama H, Imai K, et al. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: a retrospective multi-center analysis. Lung Cancer. 2020;141:107\u201313.","journal-title":"Lung Cancer"},{"key":"1899_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102205","volume":"64","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Lin Y, Fu W, He Q, Liang H, Zhong R, et al. The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non-small cell lung cancer with sensitive EGFR mutations. EClinicalMedicine. 2023;64: 102205.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"1899_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrc.2017.125","volume":"18","author":"MR Luskin","year":"2018","unstructured":"Luskin MR, Murakami MA, Manalis SR, Weinstock DM. Targeting minimal residual disease: a path to cure? Nat Rev Cancer. 2018;18(4):255\u201363.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1899_CR14","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1158\/2159-8290.CD-21-1486","volume":"12","author":"JT Zhang","year":"2022","unstructured":"Zhang JT, Liu SY, Gao W, Liu SM, Yan HH, Ji L, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discov. 2022;12(7):1690\u2013701.","journal-title":"Cancer Discov"},{"issue":"7","key":"1899_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41571-018-0004-4","volume":"15","author":"A Koch","year":"2018","unstructured":"Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, et al. Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol. 2018;15(7):459\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1899_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12\u201327.","journal-title":"Cell"},{"issue":"6","key":"1899_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41576-022-00465-w","volume":"23","author":"PD Yousefi","year":"2022","unstructured":"Yousefi PD, Suderman M, Langdon R, Whitehurst O, Davey Smith G, Relton CL. DNA methylation-based predictors of health: applications and statistical considerations. Nat Rev Genet. 2022;23(6):369\u201383.","journal-title":"Nat Rev Genet"},{"issue":"11","key":"1899_CR18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMoa0706550","volume":"358","author":"MV Brock","year":"2008","unstructured":"Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358(11):1118\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"1899_CR19","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-03-0763","volume":"10","author":"M Guo","year":"2004","unstructured":"Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, et al. Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res. 2004;10(15):5131\u20136.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1899_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12916-023-02954-z","volume":"21","author":"K Chen","year":"2023","unstructured":"Chen K, Kang G, Zhang Z, Lizaso A, Beck S, Lyskjaer I, et al. Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer. BMC Med. 2023;21(1):255.","journal-title":"BMC Med"},{"issue":"5","key":"1899_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6004\/jnccn.2015.0071","volume":"13","author":"DS Ettinger","year":"2015","unstructured":"Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 6.2015. J Nat Compr Cancer Netw JNCCN. 2015;13(5):515\u201324.","journal-title":"J Nat Compr Cancer Netw JNCCN"},{"issue":"6","key":"1899_CR22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1309\/AJCPMWGWGO34EGOD","volume":"141","author":"MT Lin","year":"2014","unstructured":"Lin MT, Mosier SL, Thiess M, Beierl KF, Debeljak M, Tseng LH, et al. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol. 2014;141(6):856\u201366.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"1899_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2353\/jmoldx.2010.090188","volume":"12","author":"AC Tsiatis","year":"2010","unstructured":"Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010;12(4):425\u201332.","journal-title":"J Mol Diagn"},{"issue":"6","key":"1899_CR24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1373\/clinchem.2009.140244","volume":"56","author":"VJ Bailey","year":"2010","unstructured":"Bailey VJ, Zhang Y, Keeley BP, Yin C, Pelosky KL, Brock M, et al. Single-tube analysis of DNA methylation with silica superparamagnetic beads. Clin Chem. 2010;56(6):1022\u20135.","journal-title":"Clin Chem"},{"issue":"1","key":"1899_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13148-020-00828-2","volume":"12","author":"C Chen","year":"2020","unstructured":"Chen C, Huang X, Yin W, Peng M, Wu F, Wu X, et al. Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules. Clin Epigenetics. 2020;12(1):39.","journal-title":"Clin Epigenetics"},{"key":"1899_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cca.2013.07.023","volume":"425","author":"B Keeley","year":"2013","unstructured":"Keeley B, Stark A, Pisanic TR 2nd, Kwak R, Zhang Y, Wrangle J, et al. Extraction and processing of circulating DNA from large sample volumes using methylation on beads for the detection of rare epigenetic events. Clin Chim Acta. 2013;425:169\u201375.","journal-title":"Clin Chim Acta"},{"key":"1899_CR27","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1158\/1078-0432.CCR-16-1371","volume":"23","author":"A Hulbert","year":"2016","unstructured":"Hulbert A, Jusue Torres I, Stark A, Chen C, Rodgers K, Lee B, et al. Early Detection of Lung Cancer using DNA Promoter Hypermethylation in Plasma and Sputum. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;23:1998.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"1899_CR28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3892\/ol.2020.11592","volume":"20","author":"W Yin","year":"2020","unstructured":"Yin W, Wang X, Li Y, Wang B, Song M, Hulbert A, et al. Promoter hypermethylation of cysteine dioxygenase type 1 in patients with non-small cell lung cancer. Oncol Lett. 2020;20(1):967\u201373.","journal-title":"Oncol Lett"},{"key":"1899_CR29","unstructured":"Genome Bioinformatics Group of UC Santa Cruz. UCSC Genome Bioinformatics 2015 Available from: http:\/\/ genome.uscs.edu"},{"issue":"42","key":"1899_CR30","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.1038\/sj.onc.1210433","volume":"26","author":"JC Brandes","year":"2007","unstructured":"Brandes JC, Carraway H, Herman JG. Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter. Oncogene. 2007;26(42):6229\u201337.","journal-title":"Oncogene"},{"key":"1899_CR31","unstructured":"Untergrasser A CI, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG Primer3web 2012 Available from: http:\/\/primer3.ut.ee\/"},{"issue":"17","key":"1899_CR32","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1158\/1078-0432.CCR-22-0391","volume":"28","author":"K Guidry","year":"2022","unstructured":"Guidry K, Vasudevaraja V, Labbe K, Mohamed H, Serrano J, Guidry BW, et al. DNA methylation profiling identifies subgroups of lung adenocarcinoma with distinct immune cell composition, DNA methylation age, and clinical outcome. Clin Cancer Res. 2022;28(17):3824\u201335.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1899_CR33","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.immuni.2022.07.001","volume":"55","author":"Z Gong","year":"2022","unstructured":"Gong Z, Li Q, Shi J, Wei J, Li P, Chang CH, et al. Lung fibroblasts facilitate pre-metastatic niche formation by remodeling the local immune microenvironment. Immunity. 2022;55(8):1483-500.e9.","journal-title":"Immunity"},{"issue":"1","key":"1899_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12943-019-1101-4","volume":"18","author":"J Kong","year":"2019","unstructured":"Kong J, Tian H, Zhang F, Zhang Z, Li J, Liu X, et al. Extracellular vesicles of carcinoma-associated fibroblasts creates a pre-metastatic niche in the lung through activating fibroblasts. Mol Cancer. 2019;18(1):175.","journal-title":"Mol Cancer"},{"issue":"7","key":"1899_CR35","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-13-2109","volume":"20","author":"J Wrangle","year":"2014","unstructured":"Wrangle J, Machida EO, Danilova L, Hulbert A, Franco N, Zhang W, et al. Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(7):1856\u201364.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1899_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/978-1-59745-522-0_22","volume":"507","author":"JD Licchesi","year":"2009","unstructured":"Licchesi JD, Herman JG. Methylation-specific PCR. Methods Mol Biol. 2009;507:305\u201323.","journal-title":"Methods Mol Biol"},{"issue":"18","key":"1899_CR37","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.1158\/1078-0432.CCR-05-0625","volume":"11","author":"SA Belinsky","year":"2005","unstructured":"Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(18):6505\u201311.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"1899_CR38","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.juro.2012.08.015","volume":"188","author":"MB Scher","year":"2012","unstructured":"Scher MB, Elbaum MB, Mogilevkin Y, Hilbert DW, Mydlo JH, Sidi AA, et al. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J Urol. 2012;188(6):2101\u20137.","journal-title":"J Urol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01899-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01899-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01899-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T15:32:41Z","timestamp":1748878361000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01899-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1899"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01899-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5808504\/v1","asserted-by":"object"}]},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol of this study was approved by the Institutional Review Board of the Second Xiangya Hospital. Written informed consent was waived due to its retrospective nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}